A photosensitizer for photodynamic therapy and its preparation method and application
By coupling phycocyanin with Zn ions, the Zn-phycocyanin lysate conjugate is formed, which solves the problem of limited photodynamic killing effect of phycocyanin, significantly improves the reactive oxygen quantum yield and kills cancer cells Effects and improve safety, suitable for the development of photodynamic anti-breast cancer drugs.
Patent Information
- Application Number
- CN202211009804.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-08-23
AI Technical Summary
As a photosensitizer for photodynamic therapy, phycocyanin has limited photodynamic killing effect, which limits its application in the treatment of cancer cells.
By coupling phycocyanin lysates with Zn ions, it forms a new photosensitizer, extracted by heating reflux, silica gel column chromatography and liquid chromatography to form a Zn-phycocyanin lysate conjugate and excites through light irradiation. Generate reactive oxygen species to kill cancer cells.
The reactive oxygen quantum yield of photosensitizers has been significantly improved, the killing effect on human breast cancer MCF-7 cells is enhanced, and safety is improved, proving that it can be used to prepare photodynamic anti-cancer drugs.
Smart Images

Figure CN115364214B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and specifically relates to a photosensitizer for photodynamic therapy, a preparation method thereof, and an application of the photosensitizer as a photodynamic anti-breast cancer drug. Background Art
[0002] Photodynamic therapy (PDT) is a new technology for treating diseases by using photosensitizers (PS) to generate energy under the stimulation of light of a specific wavelength and transfer it to oxygen to produce reactive oxygen species (ROS). PDT has become an established treatment option in specific clinical applications due to its advantages such as high accuracy, non-invasiveness, controllability, low toxicity and repeatable treatment. PS, oxygen and light play an important role in PDT, and failure to meet the requirements of any one of them will affect the effect of PDT.
[0003] Phycocyanin (PC) is a protein abundant in microalgae that has photodynamic killing effects on cancer cells, but its photodynamic killing effect is limited, which limits its development as a photosensitizer for photodynamic therapy. At present, the search for new photosensitizers for photodynamic therapy with stronger photodynamic killing effects is still the direction of researchers in the field of biomedicine. Summary of the invention
[0004] The purpose of the present invention is to provide a photosensitizer for photodynamic therapy and a preparation method and application thereof.
[0005] To achieve the above object, the present invention adopts the following technical solutions:
[0006] A photosensitizer for photodynamic therapy, which is composed of a phycocyanin lysate coupled with Zn ions; the phycocyanin lysate is obtained by breaking the thioether bond of phycocyanin and removing the protein, and the preparation method thereof comprises the following steps:
[0007] (1) Extraction
[0008] Using phycocyanin from Spirulina as raw material, the extraction was performed by heating reflux method and then filtered, and the obtained dark blue solution was concentrated by rotary evaporation and vacuum dried to obtain a crude product of phycocyanin lysate;
[0009] (2) Purification
[0010] The crude product of the phycocyanin lysate is separated and purified by silica gel column chromatography and preparative liquid chromatography, and then the purified solution is concentrated by evaporation and freeze-dried to obtain the phycocyanin lysate.
[0011] Furthermore, the heating reflux method in step (1) uses one or more of ethyl acetate, methanol, ethanol, propanol, isopropanol, glycerol, acetone and water as the extraction solvent, the solid-liquid ratio is 1 g: 10-1000 mL, the heating temperature is 10-100 ° C, and the reflux time is 1-72h.
[0012] Furthermore, in step (2), the silica gel column chromatography uses ethyl acetate / ethanol with a volume ratio of 1:4 as the mobile phase for elution; the condition parameters of the preparative liquid chromatography are: Amethyst C 18 -H column, with 60 vol% methanol solution containing 0.1 vol% acetic acid as the mobile phase, and the detection wavelength was 370 nm.
[0013] The maximum absorption peak of the UV-visible absorption spectrum of the obtained phycocyanin lysate appears in the UV region, with an absorption wavelength of 365 nm. There is also a weaker absorption peak at 620 nm in the visible region, and the absorption peak at 620 nm is lower than the absorption peak at 365 nm.
[0014] Its liquid chromatography has only two chromatographic peaks at 370 nm, one of which is a strong chromatographic peak. The purity of the strong chromatographic peak is calculated to be more than 99% by the normalization method of the peak area.
[0015] When the mass spectrum is not cleaved by cleavage energy, only one molecular peak appears, and its molecular weight is 587.3. When the phycocyanin lysate is cleaved by cleavage energy CID@20, two main fragment peaks are obtained, and their molecular weights are 299.1 and 464.2 respectively. When the cleavage energy CID@20 is increased to CID@40, three new fragment peaks are added, and their molecular weights are 271.1, 346.2 and 406.2 respectively.
[0016] Its hydrogen nuclear magnetic resonance spectrum is: 1 H NMR (500 MHz, Pyridine -d 5 ): 7.31 (s, 1H), 6.33 (d, J =2.2 Hz, 1H), 6.10 (s, 1H), 5.89 (s, 1H), 3.38 (q, J = 7.2 Hz, 1H), 3.21 (t, J = 7.1 Hz, 2H), 3.14 (t, J = 7.5 Hz, 2H), 2.89 (d, J = 7.3 Hz, 2H), 2.86 (d, J = 7.7 Hz, 2H), 2.51 (p, J=6.4 Hz, 2H), 2.16 (s, 3H), 2.11 (d, J = 4.0 Hz, 3H), 2.04 (s, 3H), 1.72 (d, J = 7.2 Hz, 3H), 1.50 (d, J = 7.6 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H);
[0017] In its fluorescence spectrum, the phycocyanin lysate does not generate fluorescence at an excitation wavelength of Ex=553 nm or Em=664 nm.
[0018] Furthermore, the preparation method of the photosensitizer comprises the following steps:
[0019] (1) dissolving the phycocyanin lysate in dimethyl sulfoxide to obtain a phycocyanin lysate solution with a concentration of 1-100 μmol / L;
[0020] (2) dissolving zinc sulfate in water to obtain a zinc sulfate solution with a concentration of 1-100 μmol / L;
[0021] (3) Mix equal volumes of the prepared phycocyanin lysate solution and zinc sulfate solution, place in a shaker, and react at 10-60 °C for 1-72 h to obtain a Zn-phycocyanin lysate conjugate.
[0022] The photosensitizer obtained above can be used to prepare photodynamic anticancer drugs, especially photodynamic anti-breast cancer drugs.
[0023] Furthermore, the light used is light with a wavelength of 400-900 nm or a mixed light source containing light with a wavelength of 400-900 nm, and the irradiation time is 5-30 min, preferably 20-30 min.
[0024] The significant advantages of the present invention are:
[0025] (1) The photosensitizer of the present invention is a novel photodynamic therapy photosensitizer. The DPBF method is used to detect the reactive oxygen quantum yield of the photosensitizer in vitro, which is 0.278, which is 113.8% higher than that of the phycocyanin lysate (0.130), indicating that the reactive oxygen quantum yield of the conjugate is greatly improved, which enables it to be used as a photodynamic therapy photosensitizer.
[0026] (2) The photosensitizer of the present invention can significantly kill human breast cancer MCF-7 cells under light irradiation conditions and can also induce apoptosis of human breast cancer MCF-7 cells, proving that it can be used to prepare photodynamic anticancer drugs.
[0027] (3) The photosensitizer of the present invention has higher safety than phycocyanin lysate. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is a liquid chromatogram of the phycocyanin lysate prepared in Example;
[0029] Figure 2 This is a mass spectrum of the phycocyanin lysate prepared in the example when it is lysed without lysing energy;
[0030] Figure 3 This is the mass spectrum of the phycocyanin lysate prepared in the example when it is cleaved by cleavage energy CID@20;
[0031] Figure 4 This is the mass spectrum of the phycocyanin lysate prepared in the example when it is cleaved by cleavage energy CID@40;
[0032] Figure 5 is a UV-visible absorption spectrum of the phycocyanin lysate and the Zn-phycocyanin lysate conjugate prepared in the example;
[0033] Figure 6 It is the fluorescence spectrum of the Zn-phycocyanin lysate conjugate prepared in the example. DETAILED DESCRIPTION
[0034] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further described below in conjunction with specific implementation methods, but the present invention is not limited thereto. Example
[0035] 1. Preparation of Phycocyanin Lysate
[0036] (1) Extraction
[0037] Using phycocyanin from Spirulina as raw material, the ethanol heating reflux method is used for extraction and then filtered to remove the green precipitate. The obtained dark blue solution is concentrated by rotary evaporation and vacuum dried to obtain the crude phycocyanin lysate. The specific operation is as follows:
[0038] Add 5.0g of phycocyanin to a 1000mL flask containing 500mL of anhydrous ethanol, and then reflux in a water bath at 88℃ for 5 hours. After the reaction is completed, place the flask in cold water to cool for 15 minutes. Filter and collect the dark blue solution. Rotate the obtained dark blue solution to dryness, add a small amount of distilled water to resuspend it, transfer it to a centrifuge tube, centrifuge it at 8000 rpm for 10 minutes, and collect the precipitate. Wash the precipitate with distilled water, collect it by centrifugation, repeat twice, and then vacuum freeze-dry it to obtain the crude phycocyanin lysate.
[0039] (2) Purification
[0040] The crude product of the phycocyanin lysate obtained is separated and purified by silica gel column chromatography and preparative liquid chromatography, and then the obtained purified solution is evaporated, concentrated, and freeze-dried to obtain the phycocyanin lysate. The specific operation is:
[0041] Weigh 60g of 200-mesh silica gel, swell it with the same volume of petroleum ether, and pour it into the column while stirring (avoid the generation of bubbles during the process). After the silica gel is allowed to settle freely, compact and balance the column with petroleum ether. After the column is balanced, weigh 10mg of the crude phycocyanin lysate, completely dissolve it with 1mL of ethanol, add 1g of 200-mesh silica gel and mix well, so that the crude phycocyanin lysate is adsorbed on the surface of the silica gel, and then placed in an oven for drying. After the solvent evaporates, load the sample with petroleum ether, and then add a layer of quartz sand on it. After the loading is completed, use ethyl acetate as the eluent to elute and remove impurities, and then use V 乙酸乙酯 :V 乙醇 =20:80 as the eluent for further elution, and the blue eluate was collected to obtain a purified phycocyanin lysate. After the purified phycocyanin lysate was concentrated, a 60% methanol solution (with 0.1% acetic acid added) was used as the mobile phase, and further purified by preparative liquid chromatography, and the blue eluate was collected, evaporated and concentrated, and finally freeze-dried to obtain a pure phycocyanin lysate, which was stored in a dark place. The chromatographic column used was Amethyst C 18 -H (4.6×250 mm, 5 μm); mobile phase flow rate was 1 mL / min; detection wavelength was 370 nm; injection volume was 100 μL.
[0042] (3) Purity test
[0043] The purity of the obtained phycocyanin lysate was 99.97%.
[0044] (4) Structural identification of phycocyanin lysate
[0045] The phycocyanin lysate prepared above was analyzed by liquid chromatography, mass spectrometry, nuclear magnetic resonance hydrogen spectrum, ultraviolet-visible absorption spectrum and fluorescence spectrum. The analysis results are as follows:
[0046] Liquid chromatography: There are only two chromatographic peaks at 370 nm, one of which is a strong chromatographic peak. The retention time of the strong chromatographic peak is 14.262 min. The purity of the strong chromatographic peak is calculated to be more than 99% by the normalization method of the peak area.
[0047] Mass spectrometry: When the phycocyanin lysate was lysed without cleavage energy, only one molecular peak appeared, and its molecular weight was 587.3. When the phycocyanin lysate was lysed with cleavage energy CID@20, two main fragment peaks were obtained, and their molecular weights were 299.1 and 464.2 respectively; when the cleavage energy was increased to CID@40, three new fragment peaks were added, and their molecular weights were 271.1, 346.2 and 406.2 respectively;
[0048] H NMR spectrum: 1 H NMR (500 MHz, Pyridine -d 5 ): 7.31 (s, 1H), 6.33 (d, J = 2.2Hz, 1H), 6.10 (s, 1H), 5.89 (s, 1H), 3.38 (q, J = 7.2 Hz, 1H), 3.21 (t, J = 7.1 Hz, 2H), 3.14 (t, J = 7.5 Hz, 2H), 2.89 (d, J = 7.3 Hz, 2H), 2.86 (d, J = 7.7 Hz, 2H), 2.51 (p, J = 6.4Hz, 2H), 2.16 (s, 3H), 2.11 (d, J = 4.0 Hz, 3H), 2.04 (s, 3H), 1.72 (d, J = 7.2 Hz, 3H), 1.50 (d, J = 7.6 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H);
[0049] UV-visible absorption spectrum: The maximum absorption peak of the obtained phycocyanin lysate appears in the ultraviolet region, and its absorption wavelength is 365 nm. There is also a weaker absorption peak at 620 nm in the visible region, and the absorption peak at 620 nm is lower than the absorption peak at 365 nm.
[0050] Fluorescence spectrum: The obtained phycocyanin lysate does not produce fluorescence at the excitation wavelength Ex=553 nm or Em=664 nm.
[0051] 2. Preparation of Zn-phycocyanin lysate
[0052] (1) Extraction of Zn-phycocyanin lysate
[0053] The obtained phycocyanin lysate was prepared into a 50 μM phycocyanin lysate solution with dimethyl sulfoxide, and zinc sulfate was prepared into a 50 μM zinc sulfate solution with distilled water. The two were then mixed in a volume ratio of 1:1, placed in a shaker, reacted at 30°C for 24 h, and then dialyzed through a 500 Da dialysis membrane to obtain a Zn-phycocyanin lysate conjugate.
[0054] (2) Structural identification of Zn-phycocyanin lysate
[0055] The Zn-phycocyanin lysate conjugate was characterized by UV-visible absorption and fluorescence spectra. The experimental results are as follows:
[0056] In the ultraviolet light region, the phycocyanin lysate has a strong absorption peak (absorption wavelength of 365nm), while the absorption peak of the Zn-phycocyanin lysate conjugate (absorption wavelength of 365nm) decreases significantly; in the visible light region, the phycocyanin lysate has only a single absorption peak (absorption wavelength of 620nm), while the Zn-phycocyanin lysate conjugate has two absorption peaks.
[0057] The Zn-phycocyanin lysate conjugate can produce fluorescence at an excitation wavelength of Ex = 582 nm or Ex = 620 nm, and the emission wavelength is Em = 632 nm. However, the phycocyanin lysate does not produce fluorescence at an excitation wavelength of Ex = 582 nm or Ex = 620 nm. This shows that the Zn-phycocyanin lysate conjugate obtained by combining the phycocyanin lysate with zinc ions can reproduce the fluorescence characteristics, and its fluorescence properties are stable, and can be used in research fields such as fluorescent reagents, flow cytometry, and immunochemistry.
[0058] 3. Determination of the Reactive Oxygen Species Quantum Yield of Zn-phycocyanin Lysate Conjugates
[0059] 1,3-Diphenylisobenzofuran (DPBF) undergoes a ring-opening reaction in the presence of ROS, causing its ultraviolet absorption at 417 nm to gradually weaken as the illumination time increases. The DPBF method was used to detect the ability of Zn-phycocyanin lysate conjugates to produce ROS. The specific operation is as follows: weigh a certain amount of DPBF powder, dissolve it in dimethyl sulfoxide, prepare a DPBF solution with a solubility of 50 µmol / L, then add a certain amount of Zn-phycocyanin lysate conjugate so that the final concentration of the conjugate is 2 µmol / L, and irradiate with 660 nm red light, with an output light power of 80 mW / cm 2 , each illumination was 5 min, illumination was performed 5 times, and the absorbance value of DPBF at 417 nm was obtained each time (denoted as A t ), as At -A0 and irradiation time t, calculate the slope k of the straight line area, and record it as the unit time bleaching rate of DPBF. Methylene blue (MB) is used as the reference substance for the production of reactive oxygen species. Under the same conditions, irradiate for 1 s each time and irradiate 3 times. The unit time bleaching rate of DPBF is also calculated. Then the quantum yield of reactive oxygen species is calculated using the following formula.
[0060] Φ △(sam) =(A MB / A sam )·(k sam / k MB )·Φ △(MB) ,
[0061] Among them, A sam and A MB Respectively represent the absorbance values of the sample to be tested and MB at the maximum absorption wavelength; k sam and k MB Represent the DPBF bleaching rate per unit time in the presence of the sample to be tested and MB, respectively; Φ △(MB) That is, the reference active oxygen quantum yield (Φ △(MB) =1.0).
[0062] The experimental results are as follows:
[0063] After adding Zn-phycocyanin lysate conjugate to DPBF solution, the absorption peak at 417 nm gradually decreased with the extension of irradiation time. It can also be observed from the appearance color that the color of DPBF solution gradually changed from the original bright green to colorless. The absorbance value at 417 nm of DPBF solution without Zn-phycocyanin lysate conjugate remained basically unchanged after being irradiated for the same time and with the same light source. This shows that Zn-phycocyanin lysate conjugate produces ROS under the excitation of 660 nm red light. It is calculated that the reactive oxygen quantum yield of Zn-phycocyanin lysate conjugate is 0.278, which is 113.8% higher than the reactive oxygen quantum yield of phycocyanin lysate (0.130). Therefore, combining phycocyanin lysate with zinc ions to form Zn-phycocyanin lysate conjugate can significantly increase the reactive oxygen quantum yield.
[0064] IV. Inhibitory effect of Zn-phycocyanin lysate on proliferation of MCF-7 cells under non-illumination and illumination conditions
[0065] Human breast cancer MCF-7 cells (purchased from Shanghai Institute of Chinese Academy of Sciences) were seeded in 96-well plates at a density of 10 cells per well. 4After culturing for 24 h, the culture medium was discarded and 5, 10, 50, 100, 150 and 200 µmol / L of Zn-phycocyanin lysate conjugate solution were added. Different irradiation wavelengths (660, 760, 808 nm and white light) were set for 20 min, and the output light power was 80 mW / cm 2 , treated with light for 24 hours as the drug group. A blank control group (not treated with light) was set up. The absorbance of each well in each drug group and blank control group was detected by MTT reagent at 490 nm, and the cell survival rate was calculated.
[0066] The experimental results are as follows:
[0067] (1) Under non-illumination conditions, with the increase of Zn-phycocyanin lysate conjugate concentration, the cell survival rate decreased slightly. When the concentration of Zn-phycocyanin lysate conjugate reached 200 μmol / L, the cell survival rate of MCF-7 was 80.87±1.04%, and its IC 50 >1000 μmol / L, indicating that the Zn-phycocyanin lysate conjugate has no significant dark toxicity to MCF-7 cells;
[0068] (2) Under light conditions, as the concentration of Zn-phycocyanin lysate conjugate increased, the cell survival rate decreased significantly. When the concentration of Zn-phycocyanin lysate conjugate was 150 μmol / L, the cell survival rate was only 17.28±1.94%. Its photo-anticancer activity was positively correlated with the concentration, and IC 50 The value was 42.91±0.57 μmol / L. In contrast, the inhibitory effect of phycocyanin lysate on the proliferation of MCF-7 cells was 2 IC under 50 The value was only 58.26±1.19 μmol / L. The experimental results showed that the Zn-phycocyanin lysate conjugate had significant phototoxicity to MCF-7 cells.
[0069] From the above experimental results, it can be seen that the Zn-phycocyanin lysate conjugate produces reactive oxygen species and induces apoptosis of cancer cells under light conditions, and its effect is stronger than that of phycocyanin lysate. Therefore, it can be used as a photodynamic anti-breast cancer drug.
[0070] To promote its application, the present invention also calculated the therapeutic index of the Zn-phycocyanin lysate conjugate according to the existing literature (Chen S, Zhang P, Liu X, et al. Towards cheminformatics-based estimation of drug therapeutic index: Predicting the protective index of anticonvulsants using a new quantitative structure-index relationship approach [J]. Journal of Molecular Graphics and Modelling, 2016, 67: 102-110).
[0071] The results showed that the therapeutic index of Zn-phycocyanin lysate conjugate for HUVEC cells was 5.856, and under the same conditions, the therapeutic index of phycocyanin lysate for HUVEC cells was 2.223. The therapeutic index is an indicator for evaluating the safety of new drugs. The larger the therapeutic index, the higher the safety of the drug. Therefore, Zn-phycocyanin lysate conjugate has higher safety than phycocyanin lysate.
[0072] For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.
Claims
1. Use of a photosensitizer in the preparation of a photodynamic anticancer drug, characterized in that: The photosensitizer is formed by coupling phycocyanin lysate with Zn ions; Its preparation comprises the following steps: (1) dissolving the phycocyanin lysate in dimethyl sulfoxide to obtain a phycocyanin lysate solution with a concentration of 1-100 μmol / L; (2) dissolving zinc sulfate in water to obtain a zinc sulfate solution with a concentration of 1-100 μmol / L; (3) Mix equal volumes of the prepared phycocyanin lysate solution and zinc sulfate solution, place in a shaker, and react at 30°C for 24 h to obtain a Zn-phycocyanin lysate conjugate; The phycocyanin lysate is obtained by breaking the thioether bond of phycocyanin and removing the protein, and its preparation includes the following steps: (1) Extraction Using phycocyanin from Spirulina as raw material, the extraction was performed by heating reflux method and then filtered, and the obtained dark blue solution was concentrated by rotary evaporation and vacuum dried to obtain a crude product of phycocyanin lysate; (2) Purification The crude product of the phycocyanin lysate is separated and purified by silica gel column chromatography and preparative liquid chromatography, and the purified solution is evaporated, concentrated, and freeze-dried to obtain the phycocyanin lysate; The heating reflux method in step (1) uses ethanol as the extraction solvent, the solid-liquid ratio is 1 g:10-1000 mL, the heating temperature is 88 °C, and the reflux time is 5 h; In step (2), the silica gel column chromatography uses ethyl acetate / ethanol with a volume ratio of 1:4 as the mobile phase for elution; The conditions of the preparative liquid chromatography are: Amethyst C 18 -H column, with 60 vol% methanol solution containing 0.1 vol% acetic acid as the mobile phase, and the detection wavelength was 370 nm; The anticancer drug is specifically an anti-breast cancer drug; When the photosensitizer is used, the light used is light with a wavelength of 400-900 nm or a mixed light source containing light with a wavelength of 400-900 nm, and the irradiation time is 20-30 min.
2. The use according to claim 1, characterized in that: In the UV-visible absorption spectrum of the phycocyanin lysate, the maximum absorption peak appears in the UV region, and its absorption wavelength is 365 nm. There is also a weaker absorption peak at 620 nm in the visible region, and the absorption peak at 620 nm is lower than the absorption peak at 365 nm. The liquid chromatography of the phycocyanin lysate has only two chromatographic peaks at 370 nm, one of which is a strong chromatographic peak, and the purity of the strong chromatographic peak is calculated to be more than 99% by the normalization method of the peak area; The mass spectrum of the phycocyanin lysate showed only one molecular peak with a molecular weight of 587.3 when the phycocyanin lysate was lysed without cleavage energy. When the phycocyanin lysate was lysed with cleavage energy CID@20, two main fragment peaks were obtained with molecular weights of 299.1 and 464.2, respectively. When the cleavage energy CID@20 was increased to CID@40, three new fragment peaks were added with molecular weights of 271.1, 346.2 and 406.2, respectively. The nuclear magnetic resonance hydrogen spectrum of the phycocyanin lysate is: 1 H NMR (500 MHz, Pyridine -d 5 ): 7.31 (s, 1H), 6.33 (d, J = 2.2 Hz, 1H), 6.10 (s, 1H), 5.89 (s, 1H), 3.38 (q, J = 7.2 Hz, 1H), 3.21 (t, J = 7.1 Hz, 2H), 3.14 (t, J = 7.5 Hz, 2H), 2.89 (d, J = 7.3 Hz, 2H), 2.86 (d, J = 7.7 Hz, 2H), 2.51 (p, J = 6.4 Hz, 2H), 2.16 (s, 3H), 2.11 (d, J = 4.0 Hz, 3H), 2.04 (s, 3H), 1.72 (d, J = 7.2 Hz, 3H), 1.50 (d, J = 7.6 Hz, 3H), 1.26 (t, J = 7.6 Hz, 3H); In the fluorescence spectrum of the phycocyanin lysate, no fluorescence is generated at an excitation wavelength Ex=553 nm or Em=664 nm.
Citation Information
Patent Citations
Preparation and application of phycocyanin extract
CN101891809A
Phycocyanin-phthalocyanine compound and preparation method and application thereof
CN103861104A
Method for extracting phycocyanobilin
CN109627201A
Novel targeted nano-particle based on phycocyanobilin and preparation method of novel targeted nano-particle
CN113230419A
Phycocyanin pigment composition
WO2021200182A1
